Treatment of mycosis fungoides with denileukin diftitox and oral bexarotene

Clinical Lymphoma and Myeloma

Volumn 6, Issue 6, 2006, Pages 488-492

  Talpur, Rakhshandra ^a   Duvic, Madeleine ^a  

^a University of Texas Health Science Center at Houston   (United States)

Author keywords

CD25; Cutaneous T cell lymphoma; Interleukin 2 receptor; Retinoid

Indexed keywords

ALPHA INTERFERON; ANTIHISTAMINIC AGENT; ATORVASTATIN; BEXAROTENE; CHLORMETHINE; DENILEUKIN DIFTITOX; DICLOXACILLIN; LEVOTHYROXINE SODIUM; PARACETAMOL; PSEUDOMONIC ACID; PSORALEN; STEROID; XIPAMIDE;

ACUTE DISEASE; ADULT; ALLERGIC REACTION; ARTICLE; CASE REPORT; DERMATITIS; DIAGNOSTIC ERROR; DRUG RESPONSE; FEMALE; FLU LIKE SYNDROME; HEPATITIS; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERTRIGLYCERIDEMIA; LIVER DYSFUNCTION; MYCOSIS FUNGOIDES; NONHUMAN; PRURITUS; PSORIASIS; SKIN ALLERGY; SKIN BIOPSY; SKIN DEFECT; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION; ULTRAVIOLET A RADIATION;

EID: 33745893772     PISSN: 15579190     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLM.2006.n.031     Document Type: Article

References (39)

1. Weinstock MA, Horm JW. Mycosis fungoides in the United States. Increasing incidence and descriptive epidemiology. JAMA 1998; 260:42-46.
2. Duvic M, Cather JC. Emerging new therapies for cutaneous T-cell lymphoma. Dermatol Clin 2000; 18:147-156.
3. Diamandidou E, Colombe M, Fayad L, et al. Prognostic factor analysis in mycosis fungoides/Sezary syndrome. J Am Acad Dermatol 1999; 40:914-924.
4. Siegel RS, Pandolfino T, Guitart J, et al. Primary cutaneous T-cell lymphoma: review and current concepts. J Clin Oncol 2000; 18:2908-2925.
5. de Coninck EC, Kim YH, Varghese A, et al. Clinical characteristics and outcome of patients with extracutaneous mycosis fungoides. J Clin Oncol 2001; 19:779-784.
6. Waters CA, Schimke PA, Snider CE, et al. Interleukin-2 receptor-targeted cytotoxicity: receptor binding requirements for entry of a diphtheria toxin-related interleukin-2 fusion protein into cells. Eur J Immunol 1990; 20:785-791.
7. Duvic M, Cather J. Immunotoxin DAB 389 Interleukin-2 (Ontak®) in the management of cutaneous T-cell lymphoma. Curr Pract Med 1999; 2:167-170.
8. Talpur R, Jones D, Alencar A, et al. CD25 expression is correlated with histological grade and response to denileukin diftitox in cutaneous T-cell lymphoma. J Invest Dermatol 2006; 126:575-583.
9. Duvic M, Martin AG, Kim Y, et al. Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma. Arch Dermatol 2001; 137:581-593.
10. Duvic M, Hymes K, Heald P, et al. Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results. J Clin Oncol 2001; 19:2456-2471.
11. Kim EJ, Hess S, Richardson SK, et al. Immunopathogenesis and therapy of cutaneous T cell lymphoma. J Clin Invest 2005; 115:798-812.
12. Duvic M, Apisarnthanarax N, Cohen DS, et al. Analysis of long-term outcomes of combined modality therapy for cutaneous T-cell lymphoma. J American Acad Dermatol 2003; 49:35-49.
13. Stadler R, Otte HG, Luger T, et al. Prospective randomized multicenter clinical trial on the use of interferon-2a plus acitretin versus interferon-2a plus PUVA in patients with cutaneous T-cell lymphoma stages I and II. Blood 1998; 92:3578-3581.
14. Singh F, Lebwohl MG. Cutaneous T-cell lymphoma treatment using bexarotene and PUVA: a case series. JAAD 2004; 51:570-573.
15. Rupoli S, Goteri G, Pulini S, et al. Long-term experience with low dose interferon-α and PUVA in the management of early mycosis fungoides. Eur J Haematol 2005; 75:136-145.
16. Foss F, Demierre MF, DiVenuti G. A phase-1 trial of bexarotene and denileukin diftitox in patients with relapsed or refractory cutaneous T-cell lymphoma. Blood 2005; 106:454-457.
17. Kaye FJ, Bunn PA Jr, Steinberg SM, et al. A randomized trial comparing combination electron-beam radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides. N Engl J Med 1989; 321:1784-1790.
18. Oyama Y, Guitart J, Kuzel TM, et al. High-dose therapy and bone marrow transplantation in cutaneous T-cell lymphoma. Hematol Oncol Clin North Am 2003; 17:1475-1483.
19. Guitart J, Wickless SC, Oyama Y, et al. Long-term remission after allogeneic hematopoietic stem cell transplantation for refractory cutaneous T-cell lymphoma. Arch Dermatol 2002; 138:1359-1365.
20. Thomsen K, Hammar H, Molin L, et al. Retinoids plus PUVA (RePUVA) and PUVA in mycosis fungoides, plaque stage. A report from the Scandinavian Mycosis Fungoides Group. Acta Derm Venereol (Stockholm) 1989; 69:536-538.
21. Knobler RM, Trautinger F, Radaszkiewicz T, et al. Treatment of cutaneous T cell lymphoma with a combination of low-dose interferon alfa-2b and retinoids. J Am Acad Dermatol 1991; 24:247-252.
22. Duvic M, Hester JP, Lemak NA. Photopheresis therapy for cutaneous T cell lymphoma. J Am Acad Dermatol 1996; 35:573-579.
23. Mahrle G, Thiele B. Retinoids in cutaneous T cell lymphomas. Dermatologica 1987; 175(suppl 1):145-150.
24. Serri F, De Simone C, Venier A, et al. Combination of retinoids and PUVA (Re-PUVA) in the treatment of cutaneous T cell lymphomas. Curr Probl Dermatol 1990; 19:252-257.
25. Thestrup-Pedersen K, Hammer R, Kaltoft K, et al. Treatment of mycosis fungoides with recombinant interferon-alpha 2a alone and in combination with etretinate. B J Dermatol 1988; 118:811-818.
26. Altomare GF, Capella GL, Pigatto PD, et al. Intramuscular low dose alpha-2B interferon and etretinate for treatment of mycosis fungoides. Int J Dermatol 1993; 32:138-141.
27. Torii H, Kaneko T, Matsuyama T, et al. Interferon-alpha (INF-alpha) and etretinate in the treatment of mycosis fungoides. J Dermatol 1994; 21:767-770.
28. Jones G, McLean J, Rosenthal D, et al. Combined treatment with oral etretinate and electron beam therapy in patients with cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome). J Am Acad Dermatol 1992; 26:960-970.
29. Molin L, Thomsen K, Volden G, et al. Retinoids and systemic chemotherapy in cases of advanced mycosis fangoides. A report from the Scandinavian Mycosis Fungoides Group. Acta Derm Venereol 1987; 67:179-182.
30. Zachariae H, Grunnet E, Thestrup-Pedersen K, et al. Oral retinoid in combination with bleomycin, cyclophosphamide, prednisone, and transfer factor in mycosis fungoides. Acta Derm Venereol (Stockholm) 1982; 62:162-164.
31. Lim HW, Harris HR. Etretinate as an effective adjunctive therapy for recalcitrant palmar/plantar hyperkeratosis in patients with erythrodermic cutaneous T cell lymphoma undergoing photopheresis. Dermatol Surg 1995; 21:597-599.
32. Stadler R, Otte HG, Luger T, et al. Prospective randomized multicenter clinical trial on the use of interferon alpha 2a plus acitretin versus interferon alpha 2a plus PUVA in patients with cutaneous T cell lymphoma stages I and II. Blood 1998; 92:3578-3581.
33. Singh F, Lebwohl MG. Cutaneous T-cell lymphoma treatment using bexarotene and PUVA: a case series. J Am Acad Dermatol 2004; 51:570-573.
34. Huber MA, Kunzi-Rapp K, Staib G, et al. Management of refractory early-stage cutaneous T-cell lymphoma (mycosis fungoides) with a combination of oral bexarotene and psoralen plus ultraviolet bath therapy. J Am Acad Dermatol 2004; 50:475-476.
35. McGinnis KS, Junkins-Hopkins JM, Crawford G, et al. Low-dose oral bexarotene in combination with low-dose interferon alfa in the treatment of cutaneous T-cell lymphoma: clinical synergism and possible immunologic mechanisms. J Am Acad Dermatol 2004; 50:375-379.
36. Talpur R, Ward S, Apisarnthanarax N, et al. Optimizing bexarotene therapy for cutaneous T-cell lymphoma. J Am Acad Dermatol 2002; 47:672-684.
37. DiVenuti GM, Foss FM. Phase I dose escalation study of Targretin and ONTAK in hematologic malignancies: upregulation of IL2R expression by low dose Targretin. Blood 2001; 98:601a (Abstract #2520).
38. Tsimberidou A, Giles F, Romaguera J, et al. Activity of interferon-alpha and isotretinoin in patients with advanced refractorylymphoid malignancies. Cancer 2004; 100:574-580.
39. Straus DJ, Duvic M, Kuzel T, et al. Results of a phase II trial of oral bexarotene combined with interferon alfa-2b for patients with cutaneous T-cell lymphoma (CTCL). Blood 2004; 104:723a (Abstract #2644).